Oral Peptide Drugs Market - Global Forecast 2026-2032

The oral peptide drugs market is redefining chronic disease therapy by merging advanced delivery science, patient-centered design, and scalable manufacturing. As treatment preferences evolve, developers, payers, and supply chain leaders recognize oral peptide drugs as a strategic modality beyond the injectable standard.

Market Snapshot: Oral Peptide Drugs Market

The Oral Peptide Drugs Market grew from USD 4.84 billion in 2025 to USD 5.20 billion in 2026 and is forecast to reach USD 7.69 billion by 2032, expanding at a CAGR of 6.82%. This consistent growth reflects mounting demand for therapies that support patient adherence, minimize administration complexity, and offer competitive real-world outcomes.

Scope & Segmentation

This report provides in-depth analysis and actionable segmentation across the oral peptide drugs market, offering an executive-ready perspective tailored for senior decision-makers.

Delivery Architectures: Focus on permeation enhancers, protease inhibitors, device-like dosage forms, and encapsulation technologies
Therapeutic Areas: Chronic diseases with high adherence requirements, and segments where oral delivery can replace injectable modalities
Regional Coverage:
- Americas: Emphasis on innovation, responsive supply chains, and clinical evidence for payers
- Europe, Middle East & Africa: Assess divergent reimbursement dynamics, cold-chain logistics, and system-level value
- Asia-Pacific: Highlight manufacturing capability expansion, growing patient populations, and local regulatory nuances
Key Market Participants: Large pharmaceutical companies, specialized drug delivery firms, and contract development and manufacturing organizations
Patient Segmentation: Evaluation of regime complexity, disease severity, comorbidities, and adoption barriers related to administration or persistence

Key Takeaways

The oral peptide drugs market is at an inflection point as science, patient needs, and manufacturing capabilities converge to make oral delivery viable for selected peptide classes.
Competitive advantage now favors companies integrating delivery-platform expertise with scalable, quality-focused manufacturing and proven clinical strategies that optimize adherence and patient experience.
Product success relies on matching specific peptide properties with appropriate delivery technologies, ensuring consistent dosing and simplified administration aligned with real-world behaviors.
Regional differentiation is critical; successful global players adapt evidence generation, product labeling, and channel strategy according to local regulatory pathways and market infrastructure.
Collaboration between innovators, manufacturing partners, and technology specialists is increasing, accelerating adoption of modular formulation components and co-development models.

Tariff Impact: How U.S. Policy Shapes Supply Chains

US tariff actions expected in 2025 are influencing sourcing and manufacturing strategies for oral peptide drugs. Companies face pressure to enhance supplier qualification, pursue dual sourcing in tariff-neutral locations, and expand domestic capacity for key materials and equipment. Operational complexity can rise, but those who invest in resilient supply chains and integrated manufacturing partnerships are better positioned to mitigate disruptions and reduce scale-up risks. Decision-makers are encouraged to revisit total cost of ownership models, accounting for regulatory readiness, change-control capabilities, and logistics reliability alongside base pricing.

Methodology & Data Sources

This report integrates structured secondary research with direct validation through interviews with executives, R&D leaders, formulation experts, and commercial professionals. The analysis triangulates scientific, regulatory, and commercial data, cross-referencing regulatory and clinical disclosures, scientific literature, and company communications to deliver robust, actionable insights for portfolio planning and investment decisions.

Why This Report Matters

Supports strategic planning with clear segmentation, regional analysis, and technology mapping tailored for the oral peptide drugs market
Equips decision-makers to navigate supply, tariff, and regulatory dynamics affecting manufacturing, distribution, and commercialization
Delivers actionable competitive benchmarks, highlighting collaboration models and product development best practices

Conclusion

Integrating delivery science, manufacturing, and patient-centricity is now essential to scale oral peptide drugs successfully. This report equips stakeholders with the insights necessary to plan, build resilience, and capture emerging opportunities as the category matures.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Peptide Drugs Market, by Form

8.1. Capsules
8.2. Oral Solutions
8.3. Oral Suspensions
8.4. Tablets

9. Oral Peptide Drugs Market, by Molecule Type

9.1. Modified Peptides
9.2. Native Peptides
9.3. Peptide Mimetics

10. Oral Peptide Drugs Market, by Distribution Channel

10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies

11. Oral Peptide Drugs Market, by Application

11.1. Cardiovascular Disorders
11.2. Diabetes
11.2.1. DPP-4 Inhibitors
11.2.2. GLP-1 Analogues
11.2.3. Insulin Peptides
11.3. Gastrointestinal Disorders
11.4. Oncology
11.4.1. Kinase Inhibitors
11.4.2. Peptide Vaccines

12. Oral Peptide Drugs Market, by End User

12.1. Clinics
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Centers

13. Oral Peptide Drugs Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Oral Peptide Drugs Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Oral Peptide Drugs Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Oral Peptide Drugs Market
17. China Oral Peptide Drugs Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. AstraZeneca PLC
18.8. Biocon
18.9. Bristol-Myers Squibb Company
18.10. Eli Lilly and Company
18.11. F. Hoffmann-La Roche Ltd.
18.12. i2o Therapeutics
18.13. Intract Pharma
18.14. Ipsen S.A.
18.15. Merck & Co., Inc.
18.16. Novartis AG
18.17. Novo Nordisk A/S
18.18. Oramed Pharmaceuticals Inc.
18.19. Pfizer Inc.
18.20. Protagonist Therapeutics, Inc.
18.21. Sanofi S.A.
18.22. Takeda Pharmaceutical Company Limited

List of Figures

FIGURE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 113. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 116. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 117. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 118. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 129. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 130. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 132. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 133. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 134. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 146. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 147. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 149. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 150. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 151. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 154. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 155. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 157. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 158. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 159. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 170. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 171. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 174. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 175. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 178. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 179. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 182. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 183. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 186. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 187. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 190. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 191. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 195. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 203. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 204. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 206. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
TABLE 207. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 208. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Oral Peptide Drugs market report include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Biocon
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
i2o Therapeutics
Intract Pharma
Ipsen S.A.
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Oramed Pharmaceuticals Inc.
Pfizer Inc.
Protagonist Therapeutics, Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Table Information

Report Attribute	Details
No. of Pages	196
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 5.2 Billion
Forecasted Market Value ( USD ) by 2032	$ 7.69 Billion
Compound Annual Growth Rate	6.8%
Regions Covered	Global
No. of Companies Mentioned	19

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Oral Peptide Drugs Market

Scope & Segmentation

Key Takeaways

Tariff Impact: How U.S. Policy Shapes Supply Chains

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Anti-amyloid Drugs Market - Global Forecast 2026-2032

Peptide API Market - Global Strategic Business Report

Fluorinated Drugs Market - Global Forecast 2026-2032

Oral Delivery of Therapeutic Peptides and Proteins

Challenges in Delivery of Therapeutic Genomics and Proteomics. Edition No. 2